Wolverine Clinical Trials LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$445,600	42
2024	Research	$490,419	39
2023	Research	$321,179	38
2022	Research	$58,482	17
2021	Research	$2,090,946	36
2020	Research	$151,151	16

Breakdown

Who paid Research payments · program years 2020–2025

Eli Lilly and Company $2,496,547 20 payments
Pfizer Inc. $575,225 94 payments
Genentech, Inc. $310,388 55 payments
Amgen Inc. $114,867 3 payments
Janssen Research & Development, LLC $60,750 16 payments

Studies the money was for Research payments · program years 2020–2025

A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $1,543,840 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $377,762 2 payments
Roche Cancer Screening Collection Study $310,388 55 payments
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-2) $303,005 4 payments
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $244,790 32 payments
A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $226,139 28 payments
A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $142,758 2 payments
A Phase 3 Multicenter Longterm Extension Study Investigating the Efficacy and Safety of Abrocitinib With Or Without Topical Medications Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis $79,658 29 payments
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies $67,418 1 payment
A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous Ly3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on A Stable Dose of Tirzepatide Or Semaglutide Who Failed to Achieve Hba1c Goal $62,329 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.